BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 352 filers reported holding BIO-TECHNE CORP in Q1 2019. The put-call ratio across all filers is 1.52 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $60,289,000 | +53.2% | 303,645 | +11.7% | 0.08% | +33.9% |
| Q4 2018 | $39,346,000 | -47.7% | 271,882 | -26.3% | 0.06% | -35.6% |
| Q3 2018 | $75,289,000 | +67.8% | 368,869 | +21.6% | 0.09% | +61.1% |
| Q2 2018 | $44,879,000 | +94.1% | 303,344 | +98.2% | 0.05% | +86.2% |
| Q1 2018 | $23,123,000 | +16.5% | 153,088 | -0.1% | 0.03% | +20.8% |
| Q4 2017 | $19,856,000 | +7.2% | 153,270 | +0.1% | 0.02% | +4.3% |
| Q3 2017 | $18,516,000 | +2.7% | 153,169 | -0.1% | 0.02% | +4.5% |
| Q2 2017 | $18,024,000 | +15.6% | 153,397 | +0.0% | 0.02% | +15.8% |
| Q1 2017 | $15,588,000 | -31.6% | 153,350 | -30.8% | 0.02% | -34.5% |
| Q4 2016 | $22,790,000 | – | 221,631 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |